Mogrify raises $16M, outlines plans to advance cell therapy platform

After raising $16 million in the first close of a series A round, Mogrify unveiled more of its cell therapy pipeline and laid out goals to enhance its cell reprogramming platform. Existing investor Ahren Innovation Capital led the round.

While Cambridge, U.K.-based Mogrify Ltd. expects this initial close to provide at least two years of runway, it’s leaving the round open for the next year. Mogrify is targeting either a second close of about the same size in the next six to nine months, or a larger raise that may take the company straight into a series B, CEO Darrin Disley told BioCentury...